Kairos Pharma
Yahoo Finance • 2 months ago
Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer News
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Bayer's share price has climbed sharply over the past year, yet the valuation checks still suggest the stock screens as cheap on s... Full story
Yahoo Finance • 2 months ago
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Combination Targets a $570M–$1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC LOS ANGELES, July 22, 2026--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage b... Full story
Yahoo Finance • 2 months ago
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
Zero Grade 3+ Toxicities associated with ENV-105 in 13 Patients; ENV-105 (Carotuximab) Demonstrates Clean Safety Profile in Combination with Osimertinib (AstraZeneca's Tagrisso®) — Advancing Kairos's Mission to Resensitize the Largest Unme... Full story
Yahoo Finance • 5 months ago
KAPA Investors Have Opportunity to Join Kairos Pharma, Ltd. Fraud Investigation with the Schall Law Firm
LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kairos Pharma, Ltd. (“Kairos” or “the Company”) (NYSE... Full story
Yahoo Finance • 7 months ago
Kairos Pharma Signs Term Sheet To Acquire Two Oncology Assets From Celyn Therapeutics; Stock Up
(RTTNews) - Kairos Pharma Ltd. (KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, announced the signing of a term sheet to acquire two clinical oncology assets from privately held Celyn Therapeutics, Inc. T... Full story